Prospective, Observational, 12-month Assessment of Canagliflozin Treatment in Type 2 Diabetes Mellitus in a Usual Clinical Practice in Canada (CANadian CAnagliflozin REgistry: CanCARE)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 13 Jun 2017
At a glance
- Drugs Canagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms CanCARE
- Sponsors Janssen Inc
- 13 Jun 2017 Results evaluating baseline characteristics and initial treatment patterns at the time of canagliflozin in the study, presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
- 10 Jun 2017 Biomarkers information updated
- 16 Dec 2016 Status changed from recruiting to active, no longer recruiting.